Clinical trial NCT05273333: Effect of Ultra-gyn® on Vulvovaginal Candidiasis
Official title: Effect of Ultra-gyn® on Vulvovaginal Candidiasis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vulvovaginal Candidiasis, Genital
Lead sponsor: Biocodex
Sponsor class: INDUSTRY
First posted: 2022-03-10
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A Prospective, Single-center, Open-label, Post-market Clinical Follow-up Study
Primary purpose: OTHER

Brief summary: The aim of this post-market clinical follow up study is to confirm the performance and the safety of Ultra-gyn® (when used in accordance with its approved labelling)


Eligibility criteria: Inclusion Criteria:

To be eligible, each patient must satisfy the following criteria:

1. Is a non-menopausal woman aged 18 to 45 years,
2. Suffering from a vulvovaginal candidiasis (according to clinical examination),
3. Who was being prescribed standard antifungal therapy for Vulvovaginal Candidiasis,
4. Has regular menstrual cycles (21-35 days) or no menstruation due to continuous use of contraception,
5. Is able to understand the study related information and to give a written informed consent,
6. Has signed the informed consent form before beginning any study procedure,
7. Agrees not to use other vaginal products than those planned in the study protocol, during participation in the study,
8. Agrees not to use a diaphragm, spermicide or latex condoms, contraceptive creams and spermicide ovules during participation in the study,
9. Uses an effective method of contraception (contraceptive steroid \[oral, patch, injection, implant\], intrauterine device, vasectomized partner, history of permanent sterilization such as tubal ligation, hysterectomy, etc.) or abstinence,
10. Has no condition that may interfere with the study assessments
11. Is affiliated to a health social security system,
12. Is able to comply with protocol requirements and respect the conditions of the study,

Exclusion Criteria:

Patients meeting at least one of the following criteria cannot be included in the study:

Criteria related to a medical condition that would compromise patient safety or data fidelity:

1. Has had a sexually transmitted disease in the 21 days preceding screening or detected on this occasion,
2. Has a history of recurrent fungaemia,
3. Has a history of recurrent vulvovaginal candidiasis (defined as more than four episodes of vulvovaginal candidiasis in the previous year or two episodes in the last six months),
4. Has had pelvic surgery in the 3 months prior to screening,
5. Has had uterine or vaginal bleeding of unknown etiology,
6. Immunocompromised,
7. Has any other severe chronic or acute medical or psychiatric condition that in the judgment of the Investigator, could interfere with the study assessments,
8. Is pregnant (positive pregnancy test at screening), has given birth less than 2 months ago or is breastfeeding,
9. Has changed her method of contraception in the 2 months prior to screening,

   Criteria related to contraindications to the product used within the study:
10. With a known allergy or presenting an hypersensitivity to one of the component of the study product,
11. Presenting a contraindication or special warning to the study product, according to the package leaflet, including concomitant use of antifungal therapy during Ultra-gyn application,

    Criteria related to medications or situations that would interfere with or compromise data fidelity
12. Has taken systemic or intravaginal antibiotic or antifungal agents (other than those prescribed during the inclusion visit) in the 14 days preceding the screening visit,
13. Is not willing to stop taking probiotics dietary supplements and food products enriched with probiotics,
14. Is planning to change her usual habits (hygiene, dietary habits, tobacco and alcohol consumption, physical activity and sexual life) during the study,
15. Has participated in an interventional clinical study in the month prior to inclusion.

Primary outcomes:
measure: To assess the effect of Ultra-gyn® in relieving the symptoms of Vulvovaginal Candidiasis
timeFrame: Day 0 to Day 30 (+/-5)
Secondary outcomes:
measure: To assess the effect of Ultra-gyn® on Candida spp
timeFrame: Day 0 and Day 30 (+/-5)
measure: To assess the effect of Ultra-gyn® on vaginal microbiota
timeFrame: Day 0 and Day 30 (+/-5)
measure: To assess the incidence of adverse effects
timeFrame: Day 1 to Day 30 (+/-5)
measure: To assess the incidence of device deficiencies
timeFrame: Day 1 to Day 30 (+/-5)
Other outcomes:
Locations:
city: Quatre Bornes
country: Mauritius
facility: IR
Study officials:
References: